Molecular imaging involves the ability to generate images of specific molecules within the body. The versatility of medical imaging modalities is continuing to increase as care givers keep older people alive longer. Age-related diseases such as cancer, stroke and heart disease represent the highest cost burden to health care in developed countries.
Kalorama Information has been noting developments in these technologies and rendering the market for them visible to market watchers and business planners. Medical Imaging Markets: Molecular Imaging offers complete market coverage of world markets for molecular imaging products for the following technologies:
For each of these modalities, the report provides current market size based on revenues to manufacturers of imaging systems used for molecular procedures, as well as forecasts of future revenues.
Interest in and use of the technology has exploded in recent years, thanks to advances in cell biology, biochemical agents, and computer analysis, and serious market watchers in medical imaging industries, as well as those serving or investing in medical imaging companies, will want to keep abreast of this new market. As part of its comprehensive coverage, Medical Imaging Markets: Molecular Imaging includes:
Big Players Team Up for Share of $6.6 Billion Molecular Imaging Market, Kalorama Information
The cost-savings associated with early disease detection and clinicians’ demand for better, more accurate diagnostic tools are key drivers for a predicted 5.8% yearly increase in the market for molecular imaging devices. According to a new report by healthcare market research publisher Kalorama Information, this market is expected to reach $6.6 billion by 2014.
Differing from traditional diagnostic tools, molecular imaging devices use biomarkers, which produce finer images that display molecular changes, allowing physicians to pinpoint diseases. Devices include nuclear medicine based PET, which renders metabolic information, and SPECT, which produces anatomical images. These devices are well known for their ability to detect the molecular basis of diseases, including neurological and cardiovascular based diseases. In tumors, they detect chemical signatures that provide an early warning. In addition, advances in these devices have recently helped to identify vulnerable plaque in at-risk cardiac patients. Kalorama notes that combining new molecular contrast agents with traditional diagnostic tools, such us Ultrasound, MRI and CT has enabled physicians to capture specific molecular pathways to track the progress of treatment.
While rapid advances in molecular imaging devices are pushing growth, physicians are even quicker to demand better products with:
“Meeting the growing demand for a better molecular imaging device is a big driver for companies seeking to break into this market,” says Bruce Carlson, publisher of Kalorama Information. “The market could even grow further if physicians’ demands are met and we see a rise in patient confidence, as this could translate into more individuals opting in for these services.”
The adoption of molecular imaging equipment is not exclusive to physicians, according to Kalorama. Pharmaceutical and biotechnology companies are also utilizing molecular imaging equipment, as it allows them to test drug candidates in vivo for mechanisms, disposition and efficacy. The big players, such as Siemens, GE Healthcare, Phillips, and Toshiba are teaming up with contrast media companies to develop the next generation of molecular imaging equipment.
Kalorama Information’s report, Molecular Imaging Markets (Market Intelligence Analysis of Market Opportunities in Molecular Imaging), contains more information on market forecasts, company profiles, and trends in the molecular imaging market.
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.Download eBook